Marshall Wace LLP Acquires 1,505,062 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

Marshall Wace LLP boosted its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 104.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,946,954 shares of the company’s stock after acquiring an additional 1,505,062 shares during the period. Marshall Wace LLP owned 0.40% of Roivant Sciences worth $34,862,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. PEAK6 LLC purchased a new stake in shares of Roivant Sciences in the 4th quarter worth about $355,000. Jump Financial LLC purchased a new stake in Roivant Sciences in the fourth quarter worth about $135,000. Ontario Teachers Pension Plan Board purchased a new stake in Roivant Sciences in the fourth quarter worth about $394,000. Mariner LLC boosted its position in Roivant Sciences by 23.7% during the 4th quarter. Mariner LLC now owns 105,972 shares of the company’s stock valued at $1,254,000 after acquiring an additional 20,299 shares in the last quarter. Finally, Barclays PLC grew its holdings in shares of Roivant Sciences by 24.0% during the 4th quarter. Barclays PLC now owns 569,892 shares of the company’s stock worth $6,742,000 after acquiring an additional 110,371 shares during the period. 64.76% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on ROIV shares. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research note on Tuesday, February 11th. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a research report on Tuesday, March 4th.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, COO Eric Venker sold 434,478 shares of the firm’s stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $10.82, for a total transaction of $4,701,051.96. Following the completion of the sale, the chief operating officer now directly owns 1,127,290 shares in the company, valued at approximately $12,197,277.80. This trade represents a 27.82 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Rakhi Kumar sold 227,500 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the completion of the transaction, the chief accounting officer now owns 163,264 shares in the company, valued at approximately $1,702,843.52. This represents a 58.22 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,395,541 shares of company stock valued at $15,028,538 in the last quarter. 7.90% of the stock is owned by insiders.

Roivant Sciences Stock Performance

ROIV stock opened at $10.15 on Friday. The firm has a 50 day moving average price of $10.33 and a 200-day moving average price of $11.17. Roivant Sciences Ltd. has a 52-week low of $8.73 and a 52-week high of $13.06. The firm has a market capitalization of $7.24 billion, a price-to-earnings ratio of -67.66 and a beta of 1.25.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, sell-side analysts forecast that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.